Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
Recent mathematical models have been developed to study the dynamics of chronic myelogenous leukemia (CML) under imatinib treatment. None of these models incorporates the anti-leukemia immune response. Recent experimental data show that imatinib treatment may promote the development of anti-leukemia...
Saved in:
Main Authors: | Peter S Kim, Peter P Lee, Doron Levy |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2008
|
Subjects: | |
Online Access: | https://doaj.org/article/7808c811147148829caaa39e2e938d5c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bosutinib in the management of chronic myelogenous leukemia
by: Keller-von Amsberg G, et al.
Published: (2013) -
Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
by: Harnicar S, et al.
Published: (2014) -
Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
by: Maiko Matsushita
Published: (2021) -
Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML).
by: Young Kwang Chae, et al.
Published: (2008) -
Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells
by: Yan Xu, et al.
Published: (2018)